On Wednesday, a Chinese pharmaceutical company said late stage drug tests showed one of the coronovirus vaccines was effective, providing positive results that could pave the way for the global rollout of hundreds of Chinese vaccine doses in the coming months is.
The company, a state-controlled company called Sinopharma, said that a vaccine candidate created by its Beijing Institute of Biological Products arm has proven a 79 percent efficacy rate in interim phase 3 trials. Sinpharma said it filed an application with Chinese regulators to allow the vaccine to be widely used.
A full stop of results was not immediately available. If supported, the results would claim that Chinese authorities have in recent times claimed that the country’s vaccines are safe and effective. Already by mid-February, officials have moved forward with plans to vaccinate 50 million people in China, according to a Chinese vaccine expert.
The campaign to develop China’s homeguard vaccine reflects the country’s technical and diplomatic ambitions. If Chinese vaccines stand up to global scrutiny, they would support the country’s claim as a peer and competitor in biomedical science from the United States and other developed countries.
Results of the Sinoform vaccine suggest that it is less effective than others approved in other countries. Nevertheless, the results are well above the 50 percent threshold, which makes the vaccine clinically effective.
Two other coronavirus vaccines, made by Modern and Pfizer-BioNotech, have already shown efficacy rates of about 95 percent. The Pfizer-BioNTech vaccine has gained authorization in more than 40 countries. The modernization vaccine has been authorized in the United States, while other countries are evaluating its test results. Russia has announced that its Sputnik V vaccine has an efficacy rate of 91 percent and has launched a mass vaccination campaign.
Beijing has stood tall on its vaccine promises to strengthen ties with developing countries considered important to China’s interests. Authorities have toured the world to provide the Chinese vaccine as a “global public good”, a charm offensive that the United States may want to counter, especially when the campaign encroaches on its backyard.
The political stakes in the vaccine race are particularly high for China’s ruling Communist Party, which has been criticized for information on official governance and for playing the virus when it first emerged in the city of Wuhan late last year Went. A successful vaccine, if made available to the world quickly, can help improve the party’s image globally and its leader Xi Jinping.